Floatz logo

Thalidomide

Neuroectodermal Tumors, Primitive

Washington University School of MedicineSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Neuroectodermal Tumors, Primitive cohort.

Asset / SponsorPhaseRating
TASADENOTUREV
DNAtrix, Inc.
Phase 2B
Cixutumumab
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
DNAtrix, Inc.
Phase 2B
Belzutifan
José Claudio Casali da Rocha
Phase 2CCC
axp107-11
University of Virginia
Phase 2CCC

View all 21 →

Same molecule, other indications

Thalidomide is also rated in:

central nervous system neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →